Redeye updates its estimates and valuation following Mentice’s Q2 2024 report. Both top-line and margins considerably beat our expectations, leading to a balanced H1 2024 after soft Q1 figures. We judge Mentice will see a more normal seasonality this year versus 2023, i.e., H2 sales and order intake should exceed H1. We nudge up our estimates and valuation.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/